The in vitro study of Chang on the HCC827 NSCLC cell line expressing mutated EGFR, suggested that the combination of gefitinib and zoledronic acid caused more tumor suppression [59]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.